Data / Drug companies / Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.: 31 products in the FDA NDC directory, labeler code 61755
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Regeneron Pharmaceuticals, Inc. (labeler code 61755) lists 31 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 19 drugs for further processing, 12 prescription drugs. Its main marketing category is drugs for further processing. The newest product started marketing on August 19, 2026.
The request: Watch Regeneron Pharmaceuticals, Inc. (FDA labeler code 61755): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 61755
- Products in commercial distribution
- 31
- Packages
- 43
- Finished drugs by generic name
- 7
- Prescription products
- 12
- Over the counter products
- 0
- Flagged as original packager
- 11 of 11 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- February 27, 2008
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 20 | 64.5% |
| Biologics (BLA) | 11 | 35.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 19 | 61.3% |
| Prescription drugs | 12 | 38.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Aflibercept | 3 | 2 |
| Alirocumab | 2 | 2 |
| Atoltivimab, maftivimab, and odesivimab-ebgn | 2 | 1 |
| Garetosmab-grts | 1 | 1 |
| Lunsotogene parvec-cwha | 1 | 1 |
| Cemiplimab-rwlc | 1 | 1 |
| Pozelimab | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 24 | 77.4% |
| Solution | 4 | 12.9% |
| Injection, powder, lyophilized, for solution | 1 | 3.2% |
| Injection, solution, concentrate | 1 | 3.2% |
| Injection | 1 | 3.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Pasatru | 61755-012 | Injection, solution, concentrate | Biologics (BLA) | August 19, 2026 |
| Otarmeni | 61755-062 | Injection, solution | Biologics (BLA) | April 23, 2026 |
| Linvoseltamab | 61755-954 | Solution | Drugs for further processing | July 2, 2025 |
| Aflibercept | 61755-950 | Injection, solution | Drugs for further processing | August 18, 2023 |
| Pozelimab | 61755-914 | Injection, solution | Drugs for further processing | August 18, 2023 |
| Eylea hd | 61755-051 | Injection, solution | Biologics (BLA) | August 18, 2023 |
| Eylea hd | 61755-050 | Injection, solution | Biologics (BLA) | August 18, 2023 |
| Veopoz | 61755-014 | Injection, solution | Biologics (BLA) | August 18, 2023 |
| Odesivimab | 61755-965 | Injection, solution | Drugs for further processing | July 29, 2021 |
| Maftivimab | 61755-964 | Injection, solution | Drugs for further processing | July 29, 2021 |
| Atoltivimab | 61755-963 | Injection, solution | Drugs for further processing | July 29, 2021 |
| Inmazeb | 61755-019 | Injection, solution | Biologics (BLA) | July 29, 2021 |
| Evinacumab | 61755-910 | Solution | Drugs for further processing | February 11, 2021 |
| Praluent | 61755-021 | Injection, solution | Biologics (BLA) | December 1, 2020 |
| Praluent | 61755-020 | Injection, solution | Biologics (BLA) | December 1, 2020 |
| Odesivimab | 61755-962 | Injection, solution | Drugs for further processing | October 14, 2020 |
| Maftivimab | 61755-961 | Injection, solution | Drugs for further processing | October 14, 2020 |
| Atoltivimab | 61755-960 | Injection, solution | Drugs for further processing | October 14, 2020 |
| Inmazeb | 61755-018 | Injection, solution | Biologics (BLA) | October 14, 2020 |
| Dupilumab | 61755-941 | Injection, solution | Drugs for further processing | October 19, 2018 |
| Cemiplimab | 61755-909 | Solution | Drugs for further processing | September 28, 2018 |
| Cemiplimab | 61755-908 | Solution | Drugs for further processing | September 28, 2018 |
| Libtayo | 61755-008 | Injection | Biologics (BLA) | September 28, 2018 |
| Sarilumab | 61755-924 | Injection, solution | Drugs for further processing | May 22, 2017 |
| Sarilumab | 61755-923 | Injection, solution | Drugs for further processing | May 22, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.